<I>N</I>-Acetyl-L-Cysteine Inhibits Marble-Burying Behavior in Mice
Tài liệu tham khảo
1 Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am. 1992;15:743–758.
1 Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am. 1992;15:743–758.
2 Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry. 1997;58:7–10.
2 Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry. 1997;58:7–10.
3 Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, et al.; World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 2003;8:7–16.
4 Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36–44.
4 Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36–44.
5 Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66:515–520.
6 Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology. 2004;174:530–538.
7 Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30:1735–1740.
10.1038/sj.npp.1300733
10.1097/JCP.0b013e3181c856de
8 Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30:34–39.
9 Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25:6389–6393.
9 Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25: 6389–6393.
10 Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6:743–749.
10.1038/nn1069
11 Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, et al. <I>N</I>-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184:254–256.
10.1254/jjp.68.65
12 Ichimaru Y, Egawa T, Sawa A. 5-HT<SUB>1A</SUB>-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol. 1995; 68:65–70.
10.1097/01.fbp.0000236266.34182.1c
13 Harasawa T, Ago Y, Itoh S, Baba A, Matsuda T. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice. Behav Pharmacol. 2006;17:637–640.
10.1016/j.ejphar.2008.01.035
14 Egashira N, Okuno R, Harada S, Matsushita M, Mishima K, Iwasaki K, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol. 2008;586:164–170.
15 LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15:105–110.